TLDR:
- British Patient Capital invested £111.4 million into 16 early-stage companies since August 2023.
- They are reducing the minimum size of funding from £30 million to £20 million.
Article Summary
British Patient Capital has provided an update on its Future Fund program, revealing investments totaling £111.4 million into 16 early-stage “deeptech” and “life sciences companies” since August 2023. The entity has also attracted £724 million of third-party capital investment during this period. Ian Connatty, Managing Director of British Patient Capital, highlights the need for growth-stage firms to receive more time and money to reach their potential, and expresses pride in the impact of the program thus far. In response to their experience, British Patient Capital is lowering the minimum size of funding from £30 million to £20 million. Additionally, sponsor investors may now include corporate venture capital funds with carry or Long-Term Incentive Plan structures in place.
British Patient Capital has undertaken a Process Evaluation and Early Impact Assessment with Ipsos UK, which suggests the potential to lead new equity funding rounds and expand the ecosystem of potential investments. This move aims to be more catalytic in driving new equity investment and nurturing the growth of promising companies. The organization remains committed to investing in the leading companies of the future and aims to continue making a tangible impact in the industry.
